CS Medica 過去の業績
過去 基準チェック /06
CS Medica's earnings have been declining at an average annual rate of -50.2%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 22.5% per year.
主要情報
-50.2%
収益成長率
-55.0%
EPS成長率
| Pharmaceuticals 業界の成長 | 7.3% |
| 収益成長率 | 22.5% |
| 株主資本利益率 | -676.9% |
| ネット・マージン | -263.8% |
| 次回の業績アップデート | 14 Nov 2024 |
最近の業績更新
Recent updates
収支内訳
CS Medica の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Jun 24 | 5 | -12 | 14 | 0 |
| 31 Mar 24 | 5 | -13 | 16 | 0 |
| 31 Dec 23 | 3 | -14 | 16 | 0 |
| 30 Sep 23 | 1 | -15 | 17 | 0 |
| 30 Jun 23 | 10 | -11 | 16 | 0 |
| 31 Mar 23 | 11 | -11 | 17 | 0 |
| 31 Dec 22 | 11 | -12 | 18 | 0 |
| 30 Sep 22 | 11 | -11 | 17 | 0 |
| 30 Jun 22 | 4 | -10 | 14 | 0 |
| 31 Mar 22 | 3 | -5 | 9 | 0 |
| 31 Dec 21 | 3 | -2 | 5 | 0 |
| 30 Sep 21 | 3 | 1 | 2 | 0 |
| 30 Jun 21 | 1 | 0 | 2 | 0 |
| 30 Sep 20 | 2 | 0 | 1 | 0 |
| 30 Sep 19 | 1 | 0 | 0 | 0 |
質の高い収益: 8G8 is currently unprofitable.
利益率の向上: 8G8 is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: 8G8 is unprofitable, and losses have increased over the past 5 years at a rate of 50.2% per year.
成長の加速: Unable to compare 8G8's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: 8G8 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
株主資本利益率
高いROE: 8G8 has a negative Return on Equity (-676.93%), as it is currently unprofitable.